Trustees of Columbia University in the City of New York’s Xilio Therapeutics XLO Stock Holding History

Trustees of Columbia University in the City of New York’s Portfolio XLO Stock Details XLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-17,831	Closed	-$210K	–	9
2025 Q3	$210K	Hold	17,831	–	–	0.03%	7
2025 Q2	$170K	Hold	17,831	–	–	0.02%	7
2025 Q1	$181K	Hold	17,831	–	–	0.03%	6
2024 Q4	$238K	Buy	+17,831	New	+$245K	0.04%	9
2023 Q4	$137K	Hold	17,831	–	–	0.29%	11
2023 Q3	$527K	Hold	17,831	–	–	0.97%	7
2023 Q2	$654K	Hold	17,831	–	–	0.96%	9
2023 Q1	$791K	Hold	17,831	–	–	1.42%	9
2022 Q4	$672K	Buy	+17,831	New	+$602K	1.39%	7

Other funds holding XLO

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

GCM

Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return

Trustees of Columbia University in the City of New York's XLO Position: Q4 2025 in Review

Trustees of Columbia University in the City of New York sold out of Xilio Therapeutics (XLO) in Q4 2025, closing a stake of 17,831 shares — an estimated $210K sold.

Trustees of Columbia University in the City of New York first reported a position in XLO in Q4 2022 and held it in 9 quarters. The position peaked at $791K in Q1 2023. 37 funds tracked by Wall St. Rank hold XLO as of Q4 2025.

Trustees of Columbia University in the City of New York reported no remaining Xilio Therapeutics position as of Q4 2025 after selling out during the quarter.
Trustees of Columbia University in the City of New York sold 17,831 Xilio Therapeutics shares in Q4 2025, an estimated $210K.
Trustees of Columbia University in the City of New York first reported a position in Xilio Therapeutics in Q4 2022 and held it in 9 quarters.
Trustees of Columbia University in the City of New York's Xilio Therapeutics position peaked at $791K in Q1 2023.
37 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q4 2025.

Based on Trustees of Columbia University in the City of New York's 13F filing for Q4 2025, filed 13 Feb 2026.